Assessing the Benefits of GLP-1 RAs

Older lady talking with her doctor.

Improving Cardiac and Renal Well-being

GLP-1 RAs are injectable glucose-lowering medications approved by the FDA for the treatment of adult patients with T2DM. In addition, GLP-1 RAs have been identified as an important drug class for not only glucose-lowering but also in reducing cardiovascular disease (CVD) events in adults with T2DM and high atherosclerotic cardiovascular disease (ASCVD) risk.1

GLP-1 RAs stimulate glucose-dependent insulin release in the gut after food intake and inhibit glucagon release with concomitant decreased gastric emptying and low risk of hypoglycemia. Important secondary effects include a decrease in appetite and food intake, which can lead to weight loss of 2 to 4 kg, and improved lipid levels, with decreased triglyceride levels and increased high-density lipoprotein levels.

Game Changers – The game that invites you to test your knowledge of GLP-1 RAs

It's time to test your knowledge about GLP-1 RAs and their benefits as they relate to type 2 diabetes.

Categories range from diagnostic criteria to Lifestyle Management. Test your knowledge and find out with this fun, engaging game.

Innovation and new ideas lightbulb concept with a question mark

Vodcast Series

GLP-1 RAs: What You Need To Know

Putting evidence into practice: Tips for starting and continuing GLP-1 RAs

Conversation around how a cardiologist or non-endocrinologist starts GLP-1 RAs. We will explore dose escalation, concerns about hypoglycemia, managing other glucose lowering agents, how to deal with adverse effects and other important topics. Claim CE Credit

Episode 7: Barriers to GLP-1 RAs

Conversation around the barriers to GLP-1 RAS. Dr. Trudy Gaillard and Dr. Monica Peek discuss adverse effects, cost, strategies when taking with other medications, social determinants of health, and educational support. Claim CE and MOC Credit

Selecting the Right Patient at the Right Time

Conversation around patient selection and GLP-1 RAs. The speakers will explore the effects of GLP-1 RAs and SGLT-2 inhibitors on clinical outcomes and CVD risk factors. Claim CE Credit

Practical Pointers to Optimize the Use of GLP-1 RAs

Conversation about the approved GLP-1 RAs to manage type 2 diabetes mellitus (T2DM). Forms of administration, contextualizing the many benefits and the risks, and indications will be discussed. Claim CE Credit

Chronic Kidney Disease and GLP-1 RAs

Discussion on the use of GLP-1 RAs in individuals with type 2 diabetes and chronic kidney disease (CKD), covering general diabetes management in CKD, potential benefits of GLP-1 RA therapy, and contemporary guideline recommendations for GLP-1 RA use in this population.

Cardiovascular Benefits of GLP-1 RAs

Conversation around specific cardiovascular risks, while distinguishing between glycemic control and cardiovascular risk reduction. We will also highlight the benefits of treatment with GLP-1 RA in patients with diabetes. Claim CE and MOC Credit

Demystifying GLP-1s

This activity focuses on the American Heart Association’s Essential 8 and glucose control. You will learn how GLP-1 RAs accelerate these glucose control goals and contribute to cardiorenal outcomes including how they work. Claim CE and MOC Credit

Obesity and GLP-1 RAs

Conversation about the global rise of obesity and its association with diabetes and the limited effectiveness of many pharmacotherapies tested for management of obesity. Claim CE Credit


1Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: e596–e646. DOI: 10.1161/CIR. 0000000000000678

This program is supported by a medical educational grant from Novo Nordisk.